Carfilzomib is a novel irreversible proteasome inhibitor (PI) used with increasing frequency
to treat patients with relapsed and/or refractory multiple myeloma (RRMM). This agent is an
effective treatment for this challenging population, but proteasome inhibition has the
potential of significant cardiac toxicity via the accumulation of intracellular protein
aggregates. Although large clinical trials have not suggested an excess of heart failure with
PI therapy, nonhuman animal studies and case reports in humans with the PI bortezomib …